Journal
FRONTIERS IN SURGERY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fsurg.2022.888630
Keywords
inflammation; lung cancer; neoplasm metastasis; neoplasm recurrence; perioperative management
Categories
Funding
- National Research Foundation of Korea (NRF) - Korea government (MSIT) [2021R1G1A1014702]
- National Research Foundation of Korea [2021R1G1A1014702] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Surgical resection is the main treatment for solid tumors, but cancer recurrence after surgery is common. Maintaining anti-tumor cell activity and proper levels of inflammatory mediators are crucial for preventing recurrence. Surgery itself and perioperative interventions can affect these physiological responses.
While surgical resection is the gold standard treatment for solid tumors, cancer recurrence after surgery is common. Immunosurveillance of remnant tumor cells is an important protective mechanism. Therefore, maintenance of anti-tumor cell activity and proper levels of inflammatory mediators is crucial. An increasing body of evidence suggests that surgery itself and perioperative interventions could affect these pathophysiological responses. Various factors, such as the extent of tissue injury, perioperative medications such as anesthetics and analgesics, and perioperative management including transfusions and methods of mechanical ventilation, modulate the inflammatory response in lung cancer surgery. This narrative review summarizes the pathophysiological mechanisms involved in cancer recurrence after surgery and perioperative management related to cancer recurrence after lung cancer surgery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available